"Muscarinic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
| Descriptor ID |
D018727
|
| MeSH Number(s) |
D27.505.519.625.120.200.500 D27.505.696.577.120.200.500
|
| Concept/Terms |
Muscarinic Antagonists- Muscarinic Antagonists
- Antagonists, Muscarinic
- Antimuscarinics
- Antimuscarinic Agents
- Agents, Antimuscarinic
- Cholinergic Muscarinic Antagonists
- Antagonists, Cholinergic Muscarinic
- Muscarinic Antagonists, Cholinergic
|
Below are MeSH descriptors whose meaning is more general than "Muscarinic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Muscarinic Antagonists".
This graph shows the total number of publications written about "Muscarinic Antagonists" by people in this website by year, and whether "Muscarinic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muscarinic Antagonists" by people in Profiles.
-
Shenot PJ. Rethinking the approach to evaluation and management of overactive bladder. Can J Urol. 2021 06; 28(3):10705.
-
Skolnik NS, Nguyen TS, Shrestha A, Ray R, Corbridge TC, Brunton SA. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting ?2-agonist bronchodilators. Postgrad Med. 2020 Mar; 132(2):198-205.
-
Strange C, Walker V, DePietro M, Tong J, Kurlander J, Carlyle M, Millette LA, Wittbrodt E. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1377-1388.
-
Bengtson LGS, DePietro M, McPheeters J, Fox KM. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy. Ther Adv Respir Dis. 2018 Jan-Dec; 12:1753466618772750.
-
Rosen JM, Alioto A, Saps M. Advances in Pain-Predominant Functional Gastrointestinal Disorders in the Adolescent. Adolesc Med State Art Rev. 2016; 27(1):34-56.
-
Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012 Oct; 13(5):327-34.
-
Casey JT, Hagerty JA, Maizels M, Chaviano AH, Yerkes E, Lindgren BW, Kaplan WE, Meyer T, Cheng EY. Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol. 2012 Oct; 188(4 Suppl):1516-20.
-
Frenkl T, Railkar R, Shore N, Bailen J, Sutherland S, Burke J, Scott BB, Ruddy M, Beals C. Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder. Neurourol Urodyn. 2012 Jan; 31(1):69-74.
-
Eisenman LM. Ethanol and vestibular stimulation reveal simple and complex aspects of cerebellar heterogeneity. Cerebellum. 2011 Sep; 10(3):475-83.
-
Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R, Maarsingh H, Zaagsma J, Meurs H. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J. 2011 Oct; 38(4):789-96.